{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:38:09Z","timestamp":1792546689055,"version":"4.5.0"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Denosumab\u2013Prolia\u00ae, Xgeva\u00ae (Amgen) is a fully human antibody to the receptor activator of the nuclear factor-K ligand (RANKL). Hepatotoxicity is extremely rare, with only one reported case of immune origin. We present a second case of hepatotoxicity resulting from an immune reaction to denosumab. A 43-year-old female was referred to the Endocrinology, Diabetes &amp; Metabolism Department for treatment of low bone mineral density (BMD) following endocrine therapy with letrozole and lucrin because of breast cancer. She developed premature menopause at the age of 36 years when she underwent a left lumpectomy due to an infiltrating duct carcinoma of the breast (T1 NO MO) and was subsequently started on endocrine therapy. Denosumab was started to prevent osteoporosis. On the third year after starting on denosumab and one month after she received the last injection, she became ill. The routine biochemical analysis showed that the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) rose appreciatively to 10 times the upper limit of normal (ULN). The gamma-glutamyl transferase (GGT) level was elevated slightly to 67 U\/L (0\u201338 U\/L). The serum gamma-globulin level was elevated to 1.72 g\/dL (0.7\u20131.6 gr\/dl), while the total bilirubin (TB) and serum albumin levels were normal. A liver biopsy revealed a moderate to severe chronic inflammatory infiltrate containing MUM-1 positive plasma cells. In addition, numerous CD-3 positive small T lymphocytes and few CD-20 positive B lymphocytes and eosinophils were seen in the portal tracts. Moderate to severe interface hepatitis, bile duct proliferation and mild portal fibrosis were also identified. The results could be consistent with the diagnosis of drug-induced liver injury (DILI).<\/jats:p>","DOI":"10.3390\/biomedicines9010076","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:39:14Z","timestamp":1610624354000},"page":"76","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Denosumab-Induced Immune Hepatitis"],"prefix":"10.3390","volume":"9","author":[{"given":"Viviana","family":"Ostrovsky","sequence":"first","affiliation":[{"name":"Diabetes, Endocrinology and Metabolic Disease Institute, Kaplan Medical Center, The Faculty of Medicine, The Hebrew University of Jerusalem, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Malnick","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine C. Kaplan Medical Center, The Faculty of Medicine, The Hebrew University of Jerusalem, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahar","family":"Ish-Shalom","sequence":"additional","affiliation":[{"name":"Department of Pathology Kaplan Medical Center, The Faculty of Medicine, The Hebrew University of Jerusalem, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadya","family":"Ziv Sokolowskaia","sequence":"additional","affiliation":[{"name":"Department of Pathology Kaplan Medical Center, The Faculty of Medicine, The Hebrew University of Jerusalem, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ady","family":"Yosepovich","sequence":"additional","affiliation":[{"name":"Department of Pathology Kaplan Medical Center, The Faculty of Medicine, The Hebrew University of Jerusalem, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Neuman","sequence":"additional","affiliation":[{"name":"In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5G 1L5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","article-title":"Denosumab, a Review in Postmenopausal Osteoporosis","volume":"35","author":"Deeks","year":"2018","journal-title":"Drug Aging."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"3","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in Postmenopausal Women with Low Bone Mineral Density","volume":"354","author":"Michael","year":"2006","journal-title":"NEJM"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"6","author":"Katarey","year":"2016","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cld.2013.07.004","article-title":"Histopathologic Manifestations of Drug-induced Hepatotoxicity","volume":"17","author":"Zhang","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"ref_7","first-page":"78","article-title":"Severe hepatocytotoxicity linked to denosumab","volume":"21","author":"Malnick","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Danan, G., and Teschke, R. (2015). RUCAM in Drug and Herb Induced Liver Injury: The Update. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010014"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","article-title":"Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: An ESCEO position paper","volume":"23","author":"Rizzoli","year":"2012","journal-title":"Osteoporos Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: Now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"ref_12","unstructured":"Zimmerman, H.J. (1999). Drugs used to treat rheumatic and musculospastic disease. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, Philadelphia. [2nd ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1210\/jc.2009-0835","article-title":"Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis","volume":"94","author":"Mundi","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hep.21971","article-title":"Increased osteoclast formation and activity by peripheral blood mononuclear cell in chronic liver disease patients with osteopenia","volume":"47","author":"Olivier","year":"2008","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: Mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1592\/phco.31.5.510","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"31","author":"Wensel","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_23","first-page":"17","article-title":"RANK-Ligand inhibitor associated osteonecrosis of the jaw","volume":"2","author":"Rashad","year":"2013","journal-title":"GMS Interdiscip Plast Reconstr. Surg. DGPW"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.oooo.2019.08.018","article-title":"Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases","volume":"129","author":"Yuan","year":"2020","journal-title":"Oral Surg. Oral Med. Oral Pathol Oral. Radiol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/1\/76\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:11:17Z","timestamp":1760159477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/1\/76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["biomedicines9010076"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9010076","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}